
Oxybutynin tablets
Form: Tablet(IR & ER)
Strength: IR: 5 mg, 10 mg; ER: 5 mg, 10 mg
Reference Brands: Ditropan, Oxybutynin XL(US)
Category: Multiple sclerosis
Oxybutynin IR and ER tablets, marketed as Ditropan and Ditropan XL, are approved in the US by the FDA and in the EU via EMA for overactive bladder management. Regulatory approval requires a detailed dossier containing clinical efficacy, safety data, manufacturing standards, and pharmacovigilance plans. In the US, the FDA reviews clinical and quality data, while the EMA ensures compliance with regional standards. For guidance on dossier preparation, regulatory pathways, and market access, visit PharmaTradz. Ensuring compliance is essential for timely approval, safe use, and global availability of oxybutynin tablets, supporting effective long-term management of bladder overactivity worldwide.
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Related Products
LamotriginevDispersible tablets
Strength: XR: 25 mg, 50 mg, 100 mg, 200 mg; IR: 25 mg, 100 mg, 200 mg, 300 mg
Form: Tablets(IR & ER)
Reference Brands: Lamictal, Lamictal XR(EU & US)
View Details Get EnquiryTolterodine tablets/ Capsules(IR & ER)
Strength: IR: 1 mg, 2 mg; ER: 2mg, 4 mg
Form: Tablets/ Capsules(IR & ER)
Reference Brands: Detrol, Detrol LA(US & EU)
View Details Get EnquiryOxybutynin tstransdermal patch
Strength: 3.9 mg/24 hours
Form: transdermal patch
Reference Brands: Oxytrol, Oxytrol for Women(US & EU)
View Details Get EnquiryDalfampridine
Strength: 10 mg
Form: Extended-Release tablets (XR)
Reference Brands: Ampyra(US)
View Details Get Enquiry